When Glenmark Pharmaceuticals launched Telma in 2003, the hypertension treatment market was already dominated by Ramipril. Doctors were familiar with the molecule, patients trusted established treatments, and competing pharmaceutical companies had strong prescription networks.
Instead of trying to win the market through a direct battle with the established leader, Glenmark took a different approach: build a differentiated brand around Telmisartan and establish its value through sustained engagement with doctors, clinical data, and consistent positioning.
From a New Entrant to a ₹1,036 Crore Franchise
Telma's growth offers an interesting lesson in pharmaceutical brand building, where prescriptions, physician trust, and long-term relevance can matter more than short-term visibility.
According to the information shared by Roshni Raju on LinkedIn, Glenmark focused on building Telma as a differentiated Telmisartan brand in a market where Ramipril was already well established. The company invested in long-term brand building within a physician-led category rather than attempting to create an overnight success.
Over time, Telma also expanded beyond a single product into a broader franchise under the mother brand. The strategy eventually translated into significant commercial scale. According to Pharmarack analysis reported by Business Standard, Telma had 16 brand extensions in 2024, with the combined franchise crossing ₹1,036 crore in sales.
The brand's journey has also received recognition beyond the pharmaceutical market. In 2015, Harvard Business Publishing developed Telma into a formal business case study, putting the Indian pharma brand into a relatively exclusive group of brands examined for their strategic approach to growth.
The franchise continued to show momentum in 2025. According to ET Pharma, Telma ranked second in India's cardiac therapy segment, recording a moving annual total of ₹447 crore and 15% value growth.
What makes the Telma story particularly relevant for marketers is the timeline. The brand did not attempt to manufacture relevance overnight. Instead, it built equity gradually around a differentiated proposition, consistent communication, and sustained engagement with prescribers.
In a category where brands are often under pressure to demonstrate quick results, Telma's journey presents a different model: build the proposition, stay consistent, and allow brand equity to compound over time.
From a single brand launched into a Ramipril-led market in 2003 to a multi-product franchise worth more than ₹1,000 crore, Telma's story demonstrates how a focused positioning strategy can evolve into long-term brand strength.
For pharmaceutical marketers, the bigger takeaway may be simple: the strongest prescription brands aren't always built by winning the loudest. They're built by staying relevant for the longest.